NEW YORK, July 27, 2017 /PRNewswire/ -- Spherix
Incorporated ("Spherix" or the "Company") (NASDAQ: SPEX), an
intellectual property development company committed to fostering of
technology, today announced that Anthony Hayes, CEO of Spherix Inc., joins the
board of directors at Hoth Therapeutics Inc.
As recently announced, Spherix purchased an interest in Hoth
Therapeutics, a development stage biopharmaceutical company focused
on unique targeted therapeutics for patients suffering from
eczema. The appointment to the Hoth board of directors is to
give Spherix representation on the board to help protect and foster
Spherix's investment.
Anthony Hayes, Spherix CEO,
stated "As Hoth continues to grow as a company, this appointment
gives Spherix involvement in Hoth to nurture and protect the
Spherix investment. The eczema space is exciting and
continuing to grow. The July 19,
2017, article in the New York
Times by Elizabeth Olson on
eczema, demonstrates the substantial demand for treatments for this
terrible affliction. We are proud to be part of the effort to
solve this medical condition and hopefully bring relief to those
suffering."
About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific
research company. Spherix is committed to advancing innovation by
participation in the development of new technology. Spherix draws
on portfolios of pioneering technology to support product
innovation.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. We are a small
company with limited financial resources and our scientific
background and abilities to implement a commercialization strategy
is subject to ever-changing market conditions and rapidly-advancing
technologies over which we have no control. While we believe that
these forward-looking statements are reasonable, market conditions
and competition in the marketplace is ever-changing and we have no
control over these influences. As a result, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC")
including, but not limited to, the Risk Factors relating to the
Company's patent business and other aspects of the Company's
business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Contact:
Investor Relations Contact:
Hayden IR, LLC
Brett Mass
Phone: (646) 536-7331
Email: investorrelations@spherix.com
www.haydenir.com
Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/spherix-announces-that-anthony-hayes-joins-the-board-of-directors-at-hoth-therapeutics-inc-300495096.html
SOURCE Spherix Incorporated